An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor outcome. Adequate model systems are required for preclinical studies to improve understanding of AML biology and to develop novel, rational treatment approaches. Xenografts in immunodeficient mice allow performing functional studies on patient-derived AML cells. We have established an improved model system that integrates serial retransplantation of patient-derived xenograft (PDX) cells in mice, genetic manipulation by lentiviral transduction, and essential quality controls by immunophenotyping and targeted resequencing of driver genes. 17/29 samples showed primary engraftment, 10/17 samples could be retransplanted and some of them allowed virtually indefinite serial transplantation. 5/6 samples were successfully transduced using lentiviruses. Neither serial transplantation nor genetic engineering markedly altered sample characteristics analyzed. Transgene expression was stable in PDX AML cells. Example given, recombinant luciferase enabled bioluminescence in vivo imaging and highly sensitive and reliable disease monitoring; imaging visualized minimal disease at 1 PDX cell in 10000 mouse bone marrow cells and facilitated quantifying leukemia initiating cells. We conclude that serial expansion, genetic engineering and imaging represent valuable tools to improve the individualized xenograft mouse model of AML. Prospectively, these advancements enable repetitive, clinically relevant studies on AML biology and preclinical treatment trials on genetically defined and heterogeneous subgroups.

[1]  C. Vascotto,et al.  Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology , 2015, Oncogene.

[2]  C. Vascotto,et al.  Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology , 2014, Oncogene.

[3]  M. Guzman,et al.  Concise Review: Leukemia Stem Cells in Personalized Medicine , 2014, Stem cells.

[4]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[5]  P. Ye,et al.  MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo. , 2014, Cancer letters.

[6]  W. Hiddemann,et al.  CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.

[7]  S. Baker,et al.  Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. , 2013, Blood.

[8]  M. Bonin,et al.  Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome , 2013, International journal of cancer.

[9]  Masahiro Nakagawa,et al.  Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. , 2013, The Journal of clinical investigation.

[10]  G. Wagemaker,et al.  In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice , 2013, PloS one.

[11]  Y. Saunthararajah,et al.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. , 2013, Blood.

[12]  O. Heidenreich,et al.  Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression , 2013, Leukemia.

[13]  Ø. Bruserud,et al.  Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. , 2013, Blood.

[14]  Jennifer Schlegel,et al.  Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission , 2013, Journal of Hematology & Oncology.

[15]  I. Jeremias,et al.  In Vivo Imaging Enables High Resolution Preclinical Trials on Patients’ Leukemia Cells Growing in Mice , 2012, PloS one.

[16]  E. Paietta,et al.  Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.

[17]  I. Jeremias,et al.  Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. , 2012, Blood.

[18]  M. Borowitz,et al.  A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. , 2012, Blood.

[19]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[20]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[21]  Olivier Harismendy,et al.  Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing , 2011, Genome Biology.

[22]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[23]  D. Teachey,et al.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. , 2011, Blood.

[24]  K. Döhner,et al.  Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice , 2011, Leukemia.

[25]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[26]  Sebastian Herzog,et al.  BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition , 2011, Nature.

[27]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[28]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[29]  M. Carroll,et al.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3 , 2010, Leukemia.

[30]  Satoshi Tanaka,et al.  Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML , 2010, Nature Biotechnology.

[31]  A. Schambach,et al.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[33]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[34]  Julie L Prior,et al.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.

[35]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[36]  M. Mann,et al.  Comparative Proteomic Phenotyping of Cell Lines and Primary Cells to Assess Preservation of Cell Type-specific Functions , 2009, Molecular & Cellular Proteomics.

[37]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[38]  Yusuke Inoue,et al.  Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. , 2008, Experimental hematology.

[39]  A Bagg,et al.  A robust xenotransplantation model for acute myeloid leukemia , 2008, Leukemia.

[40]  G. Pruneri,et al.  Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains , 2008, International journal of cancer.

[41]  P. Hwu,et al.  Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer , 2008, Proceedings of the National Academy of Sciences.

[42]  J. Gribben,et al.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. , 2008, Blood.

[43]  C. Huber,et al.  Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. , 2008, Experimental hematology.

[44]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[45]  T. Lister,et al.  AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. , 2006, Blood.

[46]  J. Dick,et al.  Biology of Normal and Acute Myeloid Leukemia Stem Cells , 2005, International journal of hematology.

[47]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[48]  J. Dick.  Acute Myeloid Leukemia Stem Cells , 2005, Annals of the New York Academy of Sciences.

[49]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[50]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.

[51]  George McNamara,et al.  Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. , 2003, Blood.

[52]  P. Meltzer,et al.  Human AML cells in NOD/SCID mice: engraftment potential and gene expression , 2002, Leukemia.

[53]  A. Martens,et al.  Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model , 2000, Leukemia.

[54]  C. Contag,et al.  Visualizing the kinetics of tumor-cell clearance in living animals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Contag,et al.  Noninvasive assessment of tumor cell proliferation in animal models. , 1999, Neoplasia.

[56]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[57]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[58]  P. Nowell,et al.  The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. , 1992, Oncogene.

[59]  C. Sawyers,et al.  Propagation of human blastic myeloid leukemias in the SCID mouse. , 1992, Blood.

[60]  Ginny Allain,et al.  Personalized medicine. , 2012, MLO: medical laboratory observer.

[61]  Asnafi,et al.  Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice , 2011 .

[62]  J. Biegel,et al.  ORIGINAL ARTICLE A robust xenotransplantation model for acute myeloid leukemia , 2009 .

[63]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. , 2005, Blood.

[64]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[65]  D. Scudiero,et al.  Development of human tumor cell line panels for use in disease-oriented drug screening. , 1988, Progress in clinical and biological research.